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Context: Free tri-iodothyronine (FT3) has been positively associated with bodymass index (BMI) in
cross-sectional studies in healthy individuals. This is difficult to reconcile with clinical findings in
pathological thyroid dysfunction.
Objective: We aimed to investigate whether childhood adiposity influences FT3 levels.
Design: Mendelian randomization using genetic variants robustly associated with BMI.
Setting: Avon Longitudinal Study of Parents and Children, a population-based birth cohort.
Participants:3,014 childrenwhohad thyroid functionmeasuredat age7,whoalsounderwentDXA
scans at ages 9.9 and 15.5 years and have genetic data available.
Main Outcome Measures: FT3.
Results: Observationally at age 7 years, BMI was positively associated with FT3:  standardized
(std)0.12 (95%CI: 0.08, 0.16) p4.02x10-10 whereas FT4 was negatively associated with BMI: 
(std)-0.08 (95%CI: -0.12, -0.04) p3.00x10-5. Thesedifferences persistedafter adjustment for age,
sex and early life environment. Genetic analysis indicated a one allele change in BMI allelic score
was associated with a 0.04 (95%CI: 0.03, 0.04) standard deviation increase in BMI (p6.4110-17).
Atage7ageneticallydetermined increase inBMIof1.89kg/m2wasassociatedwitha0.22pmol/liter
(95%CI 0.07, 0.36) increase in FT3 (p0.004) but no substantial change in FT4 0.01 mmol/liter,
(95%CI -0.37, 0.40) p0.96.
Conclusion:Our analysis shows that children with a genetically higher BMI had higher FT3 but not
FT4 levels indicating higher BMI/fat mass has a causal role in increasing FT3 levels. This may explain
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the paradoxical associations observed in observational analyses. Given rising childhood obesity
levels, this relationship merits closer scrutiny.
The relationship between pathological thyroid dysfunc-tion and body composition is well established with
hyperthyroidism associated with weight loss (1) and sub-
sequent hypothyroidism following treatment associated
with weight gain (2). There is now increasing awareness
that variation in thyroid hormone levels within and just
outside the normal population reference range is associ-
ated with differences in important health outcomes (3). In
particular, cross-sectional studies have shown that varia-
tion in thyroid status across the population reference-
range is associated with substantial differences in body
composition (3–6).
However the nature of the association between non-
pathological variation in thyroid status and body compo-
sition remains unclear. Longitudinal studies demonstrate
thatweight gain is accompaniedby increased thyroid stim-
ulating hormone (TSH) (5) and weight loss is related to
decreased TSH and also surprisingly to decreased free tri-
iodothyronine (FT3) levels (7). Elevations inTSHandFT3,
but not free thyroxine (FT4) have also been observed in
obese individuals (8, 9). More recently studies have also
shown that in healthy euthyroid adults FT3 is positively
associated with BMI and measures of adiposity whereas
FT4 is negatively associated (10–13). This finding is of
particular interest because thyroid hormones, FT3 in par-
ticular, increase energy expenditure (14) and hence would
be expected to be negatively associated with fat mass.
However as these studies were based on cross-sectional
analyses reverse causation or confounding leading to a
spurious association remains a possibility.
Genetic association studies offer an alternative to tra-
ditional epidemiological analyses. The random assort-
ment of genes that occurs during gamete formation results
in an equal distribution of confounding factors among
different genotypes. Furthermore the direction of causa-
tion is from the BMI genetic instruments onto FT3, and
cannot be due to reverse causation (a key problem in ob-
servational epidemiology) as FT3 levels cannot cause ge-
netic variation. Finally, genetic variants and their effects
are subject to relatively little measurement error or bias. A
key benefit of using this approach in this analysis is that
BMI is associated with a wide range of behavioral, social
and physiological factors that might confound its associ-
ation with FT3. Our use of genetic variants substantially
reduces the risk of this confounding (15). Importantly this
approach also enables us to clarify the direction of cau-
sation between body mass index (BMI) and FT3 that is to
assess whether changes in BMI /fat mass causally affect
thyroid status (16) or vice versa. This is information not
obtainable using standard epidemiological analysis
As alleles are largely passed from parents to offspring
independently of the environment, offspring who inherit
more alleles associated with BMI are in effect being ran-
domly assigned a higher BMIdosage.MRcan therefore be
thought of as analogous to a randomized trial with ran-
domization by genotype taking place at conception. A by-
genotype analysis is equivalent to an intention-to-treat
analysis in a randomized controlled trial (RCT), in which
individuals are analyzed according to the group they were
randomized into, independent of whether they complied
to the treatment regimen or not.
In this study, we undertook MR analyses in a large
population-based birth cohort, the Avon Longitudinal
Study of Parents and Children (ALSPAC) to examine the
nature of the relationship between BMI and FT3. We used
32 independent genetic correlates of BMI, confirmed in a
large-scale meta-analysis of genome-wide association
studies (17), to assess whether there is a causal pathway
between BMI and FT3 levels whichwould explain the par-
adoxical opposing relationship between FT3 and FT4 on
BMI in observational studies.
Materials and Methods
Participants
ALSPAC is a prospective birth cohort that enrolled over
13 000pregnantwomen in the formerCountyofAvon,UK,with
an expected delivery date between April 1991 and December
1992 (18, 19) (see www.alspac.bris.ac.uk.) The study website
contains details of all the data that is available through a fully
searchable database www.bris.ac.uk/alspac/researchers/data-
access/data-dictionary/. Ethical approval for the study was ob-
tained from the ALSPAC Ethics and Law Committee and the
Local Research Ethics Committees.
Assessment of height and body composition
Standing height was measured using a wall-mounted
Harpenden stadiometer (Holtain Ltd., Crymych, UK). BMI was
calculated as weight (in kilograms) divided by height (in meters)
squared. As a measure of adiposity BMI has several limitations
(20); in particular it does not reliably distinguish between fat and
lean mass. Therefore total fat mass was also assessed using a
Lunar Prodigy narrow fan beam densitometer to perform a
whole-body dual-energy x-ray absorptiometry (DXA) scan. Ad-
ditional details of thesemeasurements, including their reproduc-
ibility, are described elsewhere (21). The fat mass index (FMI)
was also calculated as total fat mass (in kilograms) divided by
height (in meters) squared. Data on BMI were collected at ages
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7 and 15 years with anthropometric data from DXA performed
at ages 9.9 and 15.5 years.
Laboratory Measures
Serum TSH, free T3 and free T4 were measured at age 7 years
(median age 89 months) by chemiluminescent emission using a
photomultiplier on Cobas®e601 (Roche Diagnostics, Mann-
heim Germany) in 3014 children who also had genetic data and
body composition data available. Repeat thyroid function at age
15 yearswas performed in 735 of these children (median age 185
months). Reference-ranges for adults are TSH, 0.27–4.2 mU/
liter, free T3 3.9–6.7 pmol/liter, free T4, 12–22 pmol/liter.
Genotyping
Genotyping in ALSPAC has been previously described (22).
GWAS data was generated by Sample Logistics and Genotyping
Facilities at the Wellcome Trust Sanger Institute and LabCorp
(Laboratory Corportation of America) using support from
23andMe. Single nucleotide polymorphisms (SNPs) were re-
moved if the minor allele frequency (MAF) was  1%, the call
rate was  95% or the p-value from an exact test of Hardy-
Weinberg equilibrium was  5.7  10-7. Individual samples
were excluded on the basis of incorrect sex assignment, minimal
or excessive heterozygosity, high levels of missingness and cryp-
tic relatedness (16%). Established BMI variants that had not
been genotyped directly were imputed with MACH 1.0.16
Markov Chain Haplotyping software (23, 24) using CEPH in-
dividuals from HapMap phase 2 (release 22) reference set.
Statistical Analysis
Implausible height, weight, BMI, fat mass, lean mass, blood
pressure (BP) and thyroid measurement (4 SD from the mean
for the sex and age-specific category) were considered as outliers
and recoded tomissing. TSHand fatmasswere natural log trans-
formed to approximate the normal distribution. Descriptive sta-
tistics are presented as backtransformed (geometric) means,
standard deviations (SD), medians and lower and upper quar-
tiles. All thyroid, body composition and BP variables were stan-
dardized; analyses are therefore presented as per SD.
Analyses were initially performed adjusted for age at mea-
surements and sex (model 1). Where appropriate, three further
models controlling for key potential confounders were under-
taken; model 2 also adjusted for thyroid hormone parameters,
model 3model 2 adjusted for height, measures of social class
and early life environment including home ownership, maternal
age at birth of child, maternal highest educational qualification,
maternal smoking in pregnancy, family adversity index and par-
ents and home score (Supplementary Text 1). Height was in-
cluded inmodel 3 as althoughBMIwas designed to assessweight
independently of height, it remains correlatedwith height owing
to its generalized derivation. Analysis of anthropometric rela-
tionships with thyroid hormone status at age 15 also incorpo-
rated pubertal status (model 4) which was assessed using a Tan-
ner stage questionnaire (25) at age 13.5 years (pubic hair
domain) range from 13.1 to 14.4 years.
Instrumental variable analysis
Speliotes et al previously reported32variants to be associated
withBMI (17) (SupplementalTable1).An ‘allelic score’was then
created by summing the dosages for BMI-increasing alleles
across all 32 SNPs (26). Here the dose of the effect allele at each
locus was weighted by the effect size of the variant in this inde-
pendent meta-analysis (17); these doses were then summed to
reflect the average number of effect weighted BMI increasing
alleles carried by an individual. This combined score was able to
explain a greater proportion of variance in BMI than single SNPs
(27) and served as an instrumental variable in our MR analysis.
This approach has previously been used in ALSPAC to study the
relationship between adiposity and physical activity in children
(28).
For investigating associations between the allelic score and
standardized phenotypes, continuous effects were estimated us-
ing linear regression with adjustment for models as above. An
additive genetic model was assumed since there was no evidence
for interaction effects among the SNPs combined in the allelic
score (17, 29). Although covariates are anticipated to be ran-
domly distributed with respect to genotype (16) we also exam-
ined associations between confounders and genotypes to check
the core instrumental variable assumption that the genetic in-
strument (BMI allelic score) is independent of factors that might
potentially confound the observational association (30), and al-
low for comparison with conventional observational epidemio-
logical models.
We then performed a two-stage least squares regression using
the weighted allelic score as an instrument for BMI/adiposity
using the “ivreg2” command in Stata. F-statistics from the first-
stage regression between genotype and BMI/adiposity were ex-
amined to check the assumption that the instrument is suffi-
ciently associated with the exposure to reduce the possibility of
weak instrument bias (31). Using the “ivendog’ command in
Stata theDurbin-Wu-Hausman (DWH) test for endogeneitywas
performed to compare effect estimates from the second stage of
the instrumental variable analysis and estimates from linear re-
gression. Models were repeated as described above.
Sensitivity analyses
To explore the potential distorting effects of pleiotropy in our
analysis we repeated our analyses using two independent genetic
instruments. Pleiotropy occurs when a genetic instrument has an
effect on the outcome (FT3) independently of its effect on the
exposure (adiposity), which has implications for key assump-
tions made in MR analyses (32). Similar instrumental variable
estimates acquired using two independent instruments would
provide suggestive evidence against the existence of a pleiotropic
effect, as it would be unlikely that both instruments had shared
pleiotropy (32). The two independent genetic instruments were
rs1558902 inFTO (the individual SNPwith the largest effect size
on BMI identified by Speliotes et al (17)), and a weighted allelic
score constructed from the remaining 31 SNPs associated with
BMI.
All data analysis was performed using Stata version 12.1
(STATACORP, College Station, TX).
Results
Study population and baseline characteristics
3,014 individuals (1,542 males, 1472 females) had rel-
evant thyroid, body composition and genetic data avail-
able (Figure 1). Children in our study dataset were more
likely to have lower BMI and fat mass as well as several
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highermarkersof affluenceand fewer early life events than
the remainderof theALSPACcohort (SupplementalTable
2). 473 (16.6%) of children in our study population were
obese or overweight at age 7,; 373 were classified as over-
weight with 100 classified as obese
according to cutoffs proposed by the




There was a good correlation be-
tween BMI at age 7 years and FMI at
age9years (Pearson’s correlation co-
efficient  0.73). Height and lean
mass were both greater in males
(126.5cm vs. 125.7cm P  .001)
(25.6Kgvs. 23.7KgP .001) respec-
tively, however BMI and fat mass
were greater in females (16.0 kg/m2
vs. 16.3 kg/m2 P .001) (9.46 kg vs.
7.10 kg P  .001). Baseline charac-
teristics are shown in Table 1
Figure 1. Study participants
Table 1. Baseline Characteristics







BMI age 7 (kg/m2) 16.1 1.89 16.0 1.76 16.3 2.09
Height age 7 (cm) 126.1 5.61 126.5 5.56 125.7 5.64
Weight age 7 (kg) 25.8 4.34 25.7 4.16 25.9 4.51
Fat mass measured by DXA (kg) 8.26 4.77 7.10 4.53 9.46 4.71
Body fat percentage [fat mass (kg)/weight (kg)]x1001 22.6 8.69 19.4 18.26 25.9 7.87
Lean mass measured by DXA (kg) 24.7 3.11 25.6 2.89 23.7 3.05
Age at DXA assessment (months) 90.3 3.92
Age 7 FT3 (pmol/liter) 6.28 0.62 6.22 0.62 6.34 0.62
Age 7 FT4 (pmol/liter) 15.7 1.66 15.5 1.58 15.9 1.71
Age 7 TSH (mU/liter) 2.28 0.91 2.36 0.90 2.20 0.90
Age 15 FT3 (pmol/liter) 5.84 0.74 6.19 0.69 5.50 0.63
Age 15 FT4 (pmol/liter) 15.4 1.90 15.4 1.98 15.4 1.84
Age 15 TSH (mU/liter) 2.33 1.00 2.43 1.05 2.24 0.93
Family Adversity Index2 3.71 4.45 3.73 3.87 3.69 3.80
Home Score3
0–4 (%) 3.47 2.77 4.21
5–8 (%) 23.9 23.2 24.6
9–12 (%) 72.7 74.1 71.2
Housing Status4
Owned/mortgaged (%) 85.6 85.6 85.6
Privately rented (%) 11.0 11.8 10.2
Council rented/other (%) 3.3 2.7 4.0
Maternal age at childbirth (years) 29.4 4.2 29.5 4.5 29.4 4.3
Maternal highest educational status5
Low (%) 18.4 19.3 17.4
Middle (%) 34.8 35.5 34.1
High (%) 46.8 45.2 48.5
Maternal smoking in pregnancy6
None (%) 84.5 84.3 84.7
Some (%) 15.5 15.7 15.2
Parity7
0  1 (%) 82.1 80.9 83.4
2 4 (%) 17.9 18.7 16.6
 5 (%) 0.2 0.28 0.07
1 2 children with missing data for weight at age 9, 2 323 children with missing data, 3 277 children with missing data, 4 215 children with missing
data, 5 224 children with missing data, 6 201 children with missing data, 7 226 children with missing data.
% are expressed as column %.
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Relationship between Thyroid Status and Body
Composition
BMI at age 7 years was positively associated with FT3
at age 7 years Beta () standardized (std)0.13 (95%CI
0.10, 0.16) P  5.30  10-16 and fat mass at age 9 
(std)0.18 (95%CI: 0.15, 0.21) P  4.32  10-25 even
after adjustment for confounders (Table 2). FT3 was also
positively associated with lean mass  (std)0.10
(95%CI: 0.06, 0.13) P 6.64 10-09. However, adding
fat mass to this model attenuated the association (
(std)0.02, 95%CI: –0.02, 0.04 P  .32). In contrast
adjusting for lean mass in the relationship between FT3
andBMI andFT3 and fatmass hadno substantial effect on
effect estimates  (std)0.07 (95%CI: 0.04, 0.10) P 
7.72  10-07 and  (std)0.12 (95%CI: 0.09, 0.16) P 
5.73  10-14 respectively.
FT4 was negatively associated with fat mass  (std)-
0.04 (95%CI: –0.08, –0.01) P  .02 and lean mass 
(std)-0.05 (95%CI: –0.09, –0.02) P  .002 as well as
height and weight (Table 2). No clear associations be-
tween TSH and body composition were observed even
after adjusting for confounders and other thyroid hor-
mone parameters.
Similar cross-sectional associations were also observed
with thyroidhormoneparameters at age15years andBMI
at age 15 years for FT3 and FT3:FT4 ratio, however effect
estimates were weaker (Supplemental Table 3). Much
weaker or no associations were observed with other com-
ponents of body composition. Analysis revealed that for
every 0.20 kg/m2 increase in FMI between ages 9 and 15
years there was a 0.10 pmol/l increase in FT3 (P  .005).
Genotypic associations
The “allelic score” for BMI was normally distributed
with a mean of 29.1 (SD 3.87 range 15.1–45.0) (Supple-
mental Figure 1) and explained 2.29% of the variance in
standardized BMI and 2.93%of the variance in standard-
izedFMI.Aper allele change in allelic scorewas associated
with a 0.04 (95%CI: 0.03, 0.04) SD increase in BMI (P
6.41 10-17) at age 7 years, a 0.04 SD increase (95%CI:
0.04, 0.05) in FMI (P  4.87  10-21) at age 9 years and
a 0.05 SD increase (95%CI: 0.04, 0.06) in BMI at age 15
years (P  1.16  10-16). In contrast to measures of adi-
posity, confounding factors were not associated with the
allelic score in this cohort aside from a weak association
for maternal smoking in pregnancy, likely representing a
type-1 error (Supplemental Table 4).
Mendelian Randomization
Genetic analysis demonstrated that a genetically higher
BMI of 1 SD (1.89 kg/m2) at age 7 years was associated
with a0.22pmol/liter (95%CI, 0.07, 0.36) increase inFT3
Table 2. Associations between measures of adiposity and thyroid hormone parameters at age 7
TSH (mU/liter) FT3 pmol/liter FT4 pmol/liter FT3 FT4 Ratio#




(std) 95%CI p* B(std) 95%CI p*
BMI (age 7)




0.02 0.001 0.15 0.12, 0.18
1.45 
10-20
Model 2 3014 0.02 -0.01, 0.06 0.13 0.16 0.13, 0.19 6.62  10-21 -0.10 -0.13, 0.06
1.64 
10-08 - - -
Model 3 3014 0.03 -0.004,0.07 0.09 0.12 0.08, 0.16 4.02  10-10 -0.08 -0.12, 0.04 0.00 003 0.12 0.09, 0.16 5.71  10-11
Weight (age 7)
Model 1 3014 0.02 -0.01, 0.05 0.15 0.11 0.08, 0.14 8.16  10-17 -0.04 -0.07, 0.02 0.001 0.13 0.10, 0.15 8.46  10-22
Model 2 3014 0.01 0.01, 0.04 0.35 0.13 0.11, 0.16 5.20  10-22 0.08 0.11, 0.05 6.30  10-09 - - -
Model 3 3014 0.02 0.001, 0.05 0.08 0.09 0.06, 0.13 5.62  10-10 0.05  0.08  0.03 0.0001 0.08 0.06, 0.11 2.07  10-07
Height (age 9)
Model 1 3014 0.002 0.03, 0.03 0.92 0.07 0.04, 0.10 8.07  10-06 0.03 0.06,0.002 0.03 0.09 0.06, 0.12 2.91  10-08
Model 2 3014 0.01 0.04, 0.02 0.68 0.09 0.05, 0.12 1.20  10-07 0.06 0.09, 0.03 0.0003 - - -
Model3‡ 3014 0.002 0.03, 0.03 0.99 0.08 0.05, 0.12 1.29  10-06 0.06 0.10, 0.02 0.001 0.09 0.06, 0.12 1.47  10-07
Fat mass (age 9)
Model 1 3014 0.01 0.02, 0.04 0.74 0.18 0.15, 0.21 4.32  10-25 0.04 0.08, 0.01 0.02 0.18 0.15, 0.21 1.86  10-25
Model 2 3014 0.003 0.03, 0.03 0.87 0.21 0.17, 0.24 1.17  10-30 0.10 0.13, 0.06 2.67  10-08 - - -
Model 3† 2538 0.008 0.04, 0.03 0.64 0.12 0.09, 0.16 4.02  10-12 0.07 0.10, 0.03 0.002 0.11 0.08, 0.14 8.06  10-11
FMI (age 9)
Model 1 3014 0.01 0.03, 0.04 0.75 0.17 0.13, 0.20 1.56  10-22 0.04 0.07, 0.002 0.04 0.17 0.14, 0.20 1.54  10-22
Model 2 3014 0.003 0.04, 0.03 0.84 0.19 0.16, 0.23 2.16  10-27 0.10 0.13, 0.06 2.42  10-07 - - -
Model 3† 2538 0.01 0.04, 0.02 0.65 0.13 0.09, 017 3.99  10-12 0.07 0.11, 0.03 0.002 0.12 0.08, 0.15 7.98  10-11
Lean mass (age 9)
Model 1 3014 0.01 0.02, 0.06 0.18 0.10 0.06, 0.13 6.64  10-09 0.05 0.09, 0.02 0.002 0.12 0.09, 0.16 1.73  10-13
Model 2 3014 0.02 0.02, 0.05 0.35 0.12 0.09, 0.15 3.46  10-12 0.09 0.12, 0.05 8.91  10-07 - - -
Model 3† 2538 0.02 0.01, 0.04 0.11 0.01 0.02, 0.03 0.56 0.03 0.05,-0.01 0.01 0.02 0.0001, 0.04 0.05
*Calculated using the Wald test † 476 individuals with missing data # Not adjusted for other thyroid hormone parameters ‡ Not adjusted for
height N  Number B   coefficient CI  Confidence interval p  strength of evidence against the null hypothesis of no association Model 1
adjusted for age and sex Model 2 adjusted for Model 1 and other thyroid hormone parameters Model 3 adjusted for Model 2 and height, markers
of social class and early life environment (home ownership, maternal age at birth of child, maternal highest educational qualification, maternal
smoking in pregnancy, family adversity index and parents and home score).
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(P .004) (Table 3). We did not observe strong evidence
of a departure of instrumental-variable-derived estimates
fromobservational results, asdemonstratedbyDWHtests
(p0.08), indicating similarity between observational
and MR estimates in the effect of BMI on FT3. Point es-
timates for standardized effect sizes from the instrumental
variable analysis were greater (0.30 vs. 0.13) than those
derived from basic observational analyses. Similar results
were observed when FMI at age 9 years was instrumented
(Table 3) and when assessing FT3 and adiposity data for
individuals at age 15 years (Supplemental Tables 56)
with no evidence of difference in the regression estimates
at ages 7 and 15 years (P  .88).
Genetic analysis demonstrated that a genetically higher
BMI of 1 SD did not reveal any substantial evidence of an
association with FT4  (std)0.01 (95%CI: –0.23, 0.24)
P  .96 (Table 3).
MR analysis using multiple independent
instruments
Results of genetic analysis using rs1558902 inFTO (the
individual SNP with the largest effect size on BMI) were
comparedwith those of a weighted allelic score consisting
of the remaining 31 genetic variants (Table 4) and both
revealed a positive association with individuals with a ge-
netically higher BMI having higher FT3 levels making
pleiotropy unlikely. Again no evidence of association was
observed with FT4 levels (Table 4).
The instrumented effect for FTO on FT3 showed some
difference to observational estimates, especially for both
BMI and FMI, where the instrumental variable analysis
produced larger effect estimates than the observational
analysis (DWHp0.01). There was also some evidence
that the instrumented effects of BMI on FT3 were higher
for FTO than the other 31 SNPs. An additional analysis
identified that independent pairs of variants from the 32
SNPs have instrumental variable effects that are normally
distributed (Supplemental Figure 2). However pairs of
variants which included FTO are at the upper end of this
distribution, indicating that although variation in FTO
produces a substantially higher impact on FT3 than the
average instrumental variable effect it is not an outlier.
Discussion
Our observational analyses clearly show that FT3 and FT4
have opposing strong correlationswith body composition
in childhood;withFT3beingpositively associated andFT4
negatively associatedwith fatmass andBMI.We therefore
Table 3. Associations between body mass index/fat mass index and FT3 and FT4 levels at age 7 as tested both by
conventional epidemiological approaches and through the application of instrumental variable analysis using a 32-
SNP weighted allelic BMI score as an instrument.
Adiposity Model N Observational Linear Regression Instrumental Variable Regression (Weighted Allelic Score with 32 SNPs)
B (95% CI) B (std) (95% CI) p F-Statistic
Partial




BMI(kg/m2) Model 1 3014 0.05 (0.04, 0.06) 0.13 (0.10, 0.16)
5.30 
10-16 72.4 0.009 0.22 (0.07, 0.36) 0.35 (0.11, 0.58) 0.004 0.08
Age 7 Model 2 3014 0.05 (0.04, 0.06) 0.16 (0.13, 0.19) 6.61  10-21 73.7 0.009 0.22 (0.08, 0.36) 0.35 (0.143 0.57) 0.002 0.09
Model 3† 2538 0.04 (0.03, 0.05) 0.12 (0.08, 0.16) 4.02  10-13 56.6 0.08 0.24 (0.06, 0.42) 0.38 (0.09, 0.68) 0.01 0.06
FMI(kg/m2) Model 1 3014 0.22 (0.17, 0.26) 0.17 (0.13 0.20) 1.56  10-22 100.4 0.03 0.19 (0.07, 0.31) 0.30 (0.10, 0.50) 0.002 0.21
Age 9 Model 2 3014 0.23 (0.19, 0.27) 0.19 (0.16, 0.23) 2.16  10-27 100.7 0.11 0.19 (0.08, 0.31) 0.31 (0.12, 0.50) 0.001 0.22
Model 3† 2538 0.17 (0.12, 0.22) 0.13 (0.09, 0.17) 3.99  10-12 79.5 0.09 0.20 (0.05, 0.35) 0.32 (0.08, 0.56) 0.008 0.14
FT4 age 7
BMI(kg/m2) Model 1 3014 0.07 (-0.10, 0.03) 0.05 (-0.08, 0.02) 0.001 72.4 0.01 0.01 (-0.37, 0.40) 0.01 (-0.23, 0.24) 0.96 0.58
Age 7 Model 2 3014 0.12 (-0.16, 0.08) 0.10 (-0.13, 0.06) 1.64  10-08 67.6 0.11 0.18 (-0.56, 0.20) 0.11 (-0.34, 0.12) 0.35 0.92
Model 3† 2538 0.09 (-0.14, 0.05) 0.08 (-0.12, 0.04) 0.00 003 46.8 0.10 0.11 (-0.58, 0.38) 0.06 (-0.36, 0.23) 0.68 0.92
FMI(kg/m2) Model 1 3014 0.01 (-0.02, 0.001) 0.04 (-0.07, 0.002) 0.04 100 0.02 0.01 (-0.33, 0.32) 0.004 (-0.21, 0.20) 0.97 0.81
Age 9 Model 2 3014 0.03 (-0.04, 0.02) 0.09 (-0.13, 0.06) 2.42  10-07 90.3 0.11 0.18 (-0.51, 0.14) 0.11 (-0.32, 0.09) 0.28 0.76
Model 3† 2538 0.02 (-0.03, 0.01) 0.07 (-0.11, 0.03) 0.002 74.1 0.11 0.07 (-0.47, 0.34) 0.04 (-0.28, 0.21) 0.75 0.76
† 476 individuals with missing data
N  Number
B   coefficient
CI  Confidence interval
std  Standardized
p  strength of evidence against the null hypothesis of no association
p(DWH) is the p-value of the Durbin form of the DWH test, which examines the difference between the estimates from linear regression and
instrumental variable analysis
Model 1 adjusted for age and sex Model 2 adjusted for Model 1 and other thyroid hormone parameters
Model 3 adjusted for Model 2 and height, markers of social class and early life environment (home ownership, maternal age at birth of child,
maternal highest educational qualification, maternal smoking in pregnancy, family adversity index and parents and home score).
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utilized a MR approach to investigate whether BMI (and
FMI)have a causal role in increasingFT3 levels in children.
Analysis using our genetic instrument revealed that indi-
viduals with a genetically higher BMI/fat mass had higher
FT3 levels in keepingwith observational estimates. In con-
trast there was no evidence of association between indi-
viduals with a genetically higher BMI/fat mass and FT4
levels. Interestingly the observational positive association
between BMI and FT3 appears to be substantially weaker
at age 15, however IV analysis effect estimates were more
comparable. Furthermore the effect also still appears to be
present in adults as previous studies also identified a pos-
itive association between FT3 and BMI in healthy euthy-
roid men aged between 25–45 years (10, 13). Therefore
repeating thisMR analysis in adults would be particularly
informative as would further studies comparing the biol-
ogy of fat in children and adults in this regard.
Taken together, our data suggests that higher levels of
BMI and adiposity cause an increase in serum FT3 levels-
but do not appear to influence FT4 levels. This would
explain the paradoxical opposing relationship of FT3
(positive) and FT4 (negative) with BMI and fat mass in
observational studies. It is also notable that our overall
genetic effect estimates of fat mass on FT3 were substan-
tially higher than the observational analysis. This may
indicate that the higher FT3 generated from higher fat
mass has a negative effect on fat mass, but this is a much
weaker overall effect than the positive effect of fatmass on
FT3. This is in keepingwith a recent studywhich identified
obese children have higher FT3 levels (34).
While our genetic analyses indicate the nature of the
relationship between fat mass and FT3 the mechanism of
action for increased fat mass increasing FT3 remains un-
clear. A simplistic assumption could be that increased fat
mass results in increased generation of FT3 from FT4 and
this increased FT3 production in fat leads to increased FT3
in serum. However, this would require increased DIO2
conversion of FT4 to FT3 in fat and this enzyme is ex-
pressed in brown but is not substantially expressed in
white adipose tissue (35). Alternatively increased fat mass
may result in other alterations in the HPT axis as longi-
tudinal analysis in ALSPAC has indicated that FT3 is less
influenced by TSH levels than FT4 and has greater intra-
individual variation (in preparation). Alternatively ob-
served changes in FT3 may relate in part to excess carbo-
hydrate in the diet of obese individuals (36). In addition
Table 4. Associations between body mass index/fat mass index and FT3 and FT4 levels at age 7 as tested both by
conventional epidemiological approaches and through the application of instrumental variable analyses
Adiposity Model N Linear Regression Instrumental Variable Regression (Weighted Allelic Score with 31 SNPs)
B (95% CI) B (std) (95% CI) p-Value F-Statistic
Partial
R2 B (95% CI) B(std) (95% CI)a p-Value
p-Value
(DWH)
31 SNPs (all SNPs excluding FTO)
FT3 age 7
BMI(kg/m2) Model 1 3014 0.05 (0.04, 0.06) 0.13 (0.10, 0.16) 5.30  10-16 73.6 0.008 0.19 (0.04, 0.33) 0.30 (0.07, 0.53) 0.01 0.17
Age 7 Model 2 3014 0.05 (0.04, 0.06) 0.16 (0.13, 0.19) 6.61  10-21 75.1 0.10 0.19 (0.05, 0.32) 0.30 (0.08, 0.52) 0.007 0.21
Model 3† 2538 0.04 (0.03, 0.05) 0.12 (0.08, 0.16) 3.08  10-13 57.9 0.07 0.20 (0.03, 0.38) 0.33 (0.04, 0.61) 0.02 0.14
FMI(kg/m2)† Model 1 3014 0.22 (0.17, 0.27) 0.17 (0.13, 0.20) 1.56  10-22 98.1 0.04 0.16 (0.04, 0.29) 0.26 (0.06, 0.46) 0.01 0.45
Age 9 Model 2 3014 0.23 (0.19, 0.27) 0.19 (0.16, 0.23) 2.16  10-18 98.6 0.12 0.17 (0.05, 0.28) 0.27 (0.08, 0.46) 0.06 0.43
Model 3† 2538 0.17 (0.12, 0.22) 0.13 (0.09, 0.17) 3.59  10-18 77.6 0.10 0.17 (0.03, 0.32) 0.28 (0.04, 0.51) 0.02 0.26
FT4 age 7
BMI(kg/m2) Model 1 3014 0.07 (-0.10, 0.03) 0.05 (-0.08, 0.02) 0.001 71.9 0.01 0.03 (-0.35, 0.41) 0.02 (-0.21, 0.25) 0.88 0.51
Age 7 Model 2 3014 0.12 (-0.16, 0.08) 0.10 (-0.13, 0.06) 1.64  10-08 69.9 0.11 0.14 (-0.51, 0.23) 0.09 (-0.31, 0.14) 0.46 0.90
Model 3† 2538 0.09 (-0.14, 0.05) 0.08 (-0.12, 0.04) 0.00 003 48.7 0.10 0.06 (-0.54 0.41) 0.04 (-0.33, 0.25) 0.79 0.79
FMI(kg/m2)† Model 1 3014 0.01 (-0.02, 0.001) 0.04 (-0.07, 0.002) 0.04 105 0.01 0.003 (-0.33, 0.32) 0.01 (-0.20, 0.20) 0.99 0.70
Age 9 Model 2 3014 0.03 (-0.04, 0.02) 0.09 (-0.13, 0.06) 2.42  10-07 103 0.11 0.16 (-0.49, 0.17) 0.10 (-0.29, 0.10) 0.35 0.99
Model 3† 2538 0.02 (-0.03, 0.01) 0.07 (-0.11, 0.03) 0.002 74.2 0.10 0.05 (-0.45, 0.35) 0.03 (-0.27, 0.21) 0.80 0.70
FTO SNP alone
FT3 age 7
BMI(kg/m2) Model 1 3014 0.05 (0.04, 0.06) 0.13 (0.10, 0.16) 5.30  10-16 10.6 0.64 0.61 (0.12, 1.09) 0.97 (0.20, 1.75) 0.01 0.006
Age 7 Model 2 3014 0.05 (0.04, 0.06) 0.16 (0.13, 0.19) 6.61  10-21 11.8 0.61 0.63 (0.15, 1.11) 1.02 (0.25, 21.80) 0.01 0.003
Model 3† 2538 0.04 (0.03, 0.05) 0.12 (0.08, 0.16) 3.08  10-13 9.52 0.67 0.72 (0.02, 1.43) 1.17 (0.03, 2.30) 0.04 0.007
FMI(kg/m2) Model 1 3014 0.22 (0.17, 0.27) 0.17 (0.13, 0.20) 1.56  10-22 9.87 0.31 0.48 (0.14,0.82) 0.78 (0.23, 1.32) 0.006 0.01
Age 9 Model 2 3014 0.23 (0.19, 0.27) 0.19 (0.16, 0.23) 2.16  10-78 15.9 0.26 0.50 (0.17,0.84) 0.82 (0.28, 1.36) 0.003 0.008
Model 3† 2538 0.17 (0.12, 0.22) 0.13 (0.09, 0.17) 3.59  10-18 14.6 0.24 0.52 (0.10, 0.94) 0.84 (0.16, 1.52) 0.008 0.02
FT4 age 7
BMI(kg/m2) Model 1 3014 0.07 (-0.10, 0.03) 0.05 (-0.08, 0.02) 0.001 10.6 0.01 0.21 (-1.20, 0.79) 0.13 (-0.73, 0.47) 0.68 0.82
Age 7 Model 2 3014 0.12 (-0.16, 0.08) 0.10 (-0.13, 0.06) 1.64  10-08 7.95 0.02 0.77 (-1.96, 0.41) 0.47 (-1.18, 0.25) 0.20 0.28
Model 3† 2538 0.09 (-0.14, 0.05) 0.08 (-0.12, 0.04) 0.00 003 5.27 0.01 0.68 (-2.16, 0.83) 0.41 (-1.33, 0.50) 0.37 0.45
FMI(kg/m2) Model 1 3014 0.01 (-0.02, 0.001) 0.04 (-0.07, 0.002) 0.04 18.1 0.01 0.20 (-1.00, 0.60) 0.12 (-0.61, 0.31 0.63 0.74
Age 9 Model 2 3014 0.03 (-0.04, 0.02) 0.09 (-0.13, 0.06) 2.42  10-07 14.2 0.03 0.65 (-1.56, 0.26) 0.39 (-0.94, 0.16) 0.16 0.27
Model 3† 2538 0.02 (-0.03, 0.01) 0.07 (-0.11, 0.03) 0.002 11.2 0.07 0.50 (-1.55, 0.56) 0.30 (-0.93, 0.35) 0.36 0.49
† 476 individuals with missing data
B   coefficient, CI  Confidence interval, std  Standardized, p  strength of evidence against the null hypothesis of no association
P (DWH) is the p-value of the Durbin form of the DWH test, which examines the difference between the estimates from linear regression and
instrumental variable analysis Model 1 adjusted for age and sex, Model 2 adjusted for Model 1 and other thyroid hormone parameters, Model 3
adjusted for Model 2 and height markers of social class and early life environment (home ownership, maternal age at birth of child, maternal
highest educational qualification, maternal smoking in pregnancy, family adversity index and parents and home score).
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our analysis showed children have higher FT3 levels than
adultswithalmost25%of childrenhavingaFT3above the
adult reference-range. This implies that other factors in-
fluenceFT3 levels in young childrenalthough fatmassmay
still have a substantial role. Further insight may be avail-
able from whole genome sequence analysis of body mass
and thyroid function, however they are unlikely to sub-
stantially increase the variance explained at present (37).
Although the MR method is more resistant to reverse
causation and confounding than traditional observational
epidemiological studies, there are limitations to this ap-
proach. These include population stratification, pleiot-
ropy (genes influencing multiple phenotypes), canaliza-
tion (the ability of a population to produce the same
phenotype regardless of variability of its environment or
genotype), inadequate power and linkage disequilibrium
(16, 38). Polygenic score analyses for TSH and FT4, have
not revealed a common genetic determination with met-
abolic and anthropometric measures (37) although FT3
has not been studied it is unlikely it shares a common
genetic architecture (pleiotropy) to fatmass.Our use of 32
independent alleles in determining the gene score, sub-
stantially reduced the risk of shared pleiotropy and link-
age-disequilibrium-induced confounding (32). Further-
more our use of two separate genetic instruments
substantially reduced the risk of pleiotropy. Another lim-
itation was that we did not have data on thyroid function,
body composition or genetic architecture in a substantial
number of children in the ALSPAC cohort. However this
would only lead to bias if the causal effects of higher fat
mass increasing FT3 levels are different in the children not
studied in this study. Although we cannot fully exclude
this therewas no substantial difference in ourmodels after
adjustment for relevant socio-economic confounders. Fur-
thermore positive associations between adiposity and FT3
were also observed when using different instrument com-
binations, suggesting that there is not a systematic and
biasing effect of pleiotropy in this case. With regard to
measurement of free thyroid hormones, biases have been
reported (39), while measured levels of free thyroid hor-
mones in our study may not be entirely independent from
thyroid binding globulin levels, the striking difference ob-
served in the associations between BMI allelic score and
FT3 and FT4 makes a substantial impact from thyroid
binding globulin in our genetic analysis unlikely. Previous
analyses have also identified the association between thy-
roid hormone parameters and body composition was
largely independent of thyroid binding globulin (11). Po-
tentially FT3 levels may be reduced in children with recent
illness before blood sampling but this would have likely
biased our genetic associations to the null.
As well as providing insight into the regulation of FT3
in children, our findings are potentially clinically relevant.
Childhood obesity is common and rising (40) and in-
creased FT3 levels arising from increasing fat mass may
have long-term consequences, particularly at the popula-
tion-level as evenmodest variation in thyroid statuswithin
the population reference-range has adverse phenotypic ef-
fects (3).
In conclusion our analysis has indicated that BMI and
adiposity causally increase FT3 levels in children. More
research is required to identify the causal mechanisms for
this and the consequences of childhood obesity on this
relationship.
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